• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Corcept Therapeutics Incorporated - Common Stock (NQ:CORT)

    76.06 +2.73 (+3.72%)
    Streaming Delayed Price Updated: 2:04 PM EDT, Jun 9, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 410,511
    Open 73.96
    Bid (Size) 75.98 (500)
    Ask (Size) 76.08 (100)
    Prev. Close 73.33
    Today's Range 73.62 - 76.25
    52wk Range 28.66 - 91.00
    Shares Outstanding 115,926,629
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Corcept Presents New Data at ADA: Improved Outcomes in Patients Receiving a GLP-1 with Difficult-to-Control Type 2 Diabetes and Hypercortisolism Treated with Korlym®
    From Corcept Therapeutics Incorporated
    Via Business Wire
    News headline image
    1 of Wall Street’s Favorite Stocks with Exciting Potential and 2 We Question
    The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%. But investors should take these f... 
    Via StockStory

    Performance

    YTD
    +99.1%
    +99.1%
    1 Month
    +48.6%
    +48.6%
    3 Month
    +123.8%
    +123.8%
    6 Month
    -8.3%
    -8.3%
    1 Year
    +7.8%
    +7.8%

    More News

    Read More
    News headline image
    Corcept Presents New Data at ASCO 2026: Lifyorli™ Overall Survival Across All Subgroups of Patients with Platinum-Resistant Ovarian Cancer, Including Those with Recent Taxane Exposure
    From Corcept Therapeutics Incorporated
    Via Business Wire
    News headline image
    Corcept to Resubmit its New Drug Application for Relacorilant as a Treatment for Patients with Cushing’s Syndrome
    From Corcept Therapeutics Incorporated
    Via Business Wire
    Corcept Therapeutics (NASDAQ:CORT) Revenue Miss Leads to Q1 Net Loss, But Guidance Upgrade and Lifyorli Launch Signal Strong Momentum ↗
    Via Chartmill
    News headline image
    3 Reasons to Sell CORT and 1 Stock to Buy Instead
    Via StockStory
    News headline image
    3 High-Flying Stocks We Think Twice About
    Via StockStory
    News headline image
    Corcept (CORT) Q1 2026 Earnings Transcript ↗
    Via The Motley Fool
    News headline image
    Corcept (CORT) Q4 2025 Earnings Transcript ↗
    Via The Motley Fool
    News headline image
    Corcept (CORT) Q1 2025 Earnings Transcript ↗
    Via The Motley Fool
    News headline image
    Corcept (CORT) Q2 2025 Earnings Transcript ↗
    Via The Motley Fool
    News headline image
    CORT Q1 Deep Dive: Early Lifyorli Launch and Endocrinology Momentum Offset Margin Pressures
    Via StockStory
    News headline image
    Corcept (NASDAQ:CORT) Misses Q1 CY2026 Revenue Estimates
    Via StockStory
    News headline image
    Corcept Phase 2 Study of Dazucorilant Demonstrates Two-Year Overall Survival Benefit in Patients with Amyotrophic Lateral Sclerosis
    From Corcept Therapeutics Incorporated
    Via Business Wire
    News headline image
    Corcept Therapeutics Announces First Quarter Financial Results and Provides Corporate Update
    From Corcept Therapeutics Incorporated
    Via Business Wire
    News headline image
    Corcept Earnings: What To Look For From CORT
    Via StockStory
    Topics Artificial Intelligence
    News headline image
    Corcept Therapeutics to Announce First Quarter Financial Results, Provide Corporate Update and Host Conference Call
    From Corcept Therapeutics Incorporated
    Via Business Wire
    News headline image
    INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Corcept Therapeutics Incorporated of Class Action Lawsuit and Upcoming Deadlines – CORT
    From Pomerantz LLP
    Via GlobeNewswire
    News headline image
    Corcept to Present New Data from Pivotal Phase 3 ROSELLA Trial of Lifyorli™ (Relacorilant) in Patients with Platinum-Resistant Ovarian Cancer at ASCO 2026
    From Corcept Therapeutics Incorporated
    Via Business Wire
    News headline image
    CORCEPT DEADLINE TODAY: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Corcept Therapeutics Incorporated Investors with Losses in Excess of $100K to Secure Counsel Before Important April 21 Deadline in Securities Class Action – CORT
    From The Rosen Law Firm PA
    Via GlobeNewswire
    News headline image
    1 Cash-Producing Stock for Long-Term Investors and 2 We Ignore
    Via StockStory
    News headline image
    CORCEPT DEADLINE TOMORROW: Bragar Eagel & Squire, P.C. Urges Corcept Therapeutics Incorporated Investors to Contact the Firm Regarding Their Rights Before April 21st
    From Bragar Eagel & Squire
    Via GlobeNewswire
    News headline image
    Revvity, Bio-Techne, Corcept, Supernus Pharmaceuticals, and Phibro Animal Health Shares Skyrocket, What You Need To Know
    Via StockStory
    Topics Economy
    News headline image
    Deadline Soon: Corcept Therapeutics Incorporated (CORT) Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit
    From The Law Offices of Frank R. Cruz
    Via Business Wire
    News headline image
    Corcept Therapeutics Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Corcept Therapeutics Incorporated - CORT
    From SkyMedia, LLC
    Via GlobeNewswire

    Frequently Asked Questions

    Is Corcept Therapeutics Incorporated - Common Stock publicly traded?
    Yes, Corcept Therapeutics Incorporated - Common Stock is publicly traded.
    What exchange does Corcept Therapeutics Incorporated - Common Stock trade on?
    Corcept Therapeutics Incorporated - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Corcept Therapeutics Incorporated - Common Stock?
    The ticker symbol for Corcept Therapeutics Incorporated - Common Stock is CORT on the Nasdaq Stock Market
    What is the current price of Corcept Therapeutics Incorporated - Common Stock?
    The current price of Corcept Therapeutics Incorporated - Common Stock is 76.06
    When was Corcept Therapeutics Incorporated - Common Stock last traded?
    The last trade of Corcept Therapeutics Incorporated - Common Stock was at 06/09/26 02:04 PM ET
    What is the market capitalization of Corcept Therapeutics Incorporated - Common Stock?
    The market capitalization of Corcept Therapeutics Incorporated - Common Stock is 8.82B
    How many shares of Corcept Therapeutics Incorporated - Common Stock are outstanding?
    Corcept Therapeutics Incorporated - Common Stock has 9B shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.